Stephens Inc. AR Purchases New Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Stephens Inc. AR acquired a new stake in Blueprint Medicines Co. (NASDAQ:BPMC) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 3,684 shares of the biotechnology company’s stock, valued at approximately $321,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BPMC. Wellington Management Group LLP boosted its stake in Blueprint Medicines by 22.5% in the third quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company’s stock valued at $366,726,000 after acquiring an additional 729,055 shares during the last quarter. State Street Corp boosted its stake in Blueprint Medicines by 16.2% in the third quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company’s stock valued at $255,827,000 after acquiring an additional 385,818 shares during the last quarter. Jennison Associates LLC bought a new position in Blueprint Medicines in the fourth quarter valued at approximately $31,417,000. Jacobs Levy Equity Management Inc. boosted its stake in Blueprint Medicines by 161.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 496,087 shares of the biotechnology company’s stock valued at $45,888,000 after acquiring an additional 306,079 shares during the last quarter. Finally, Eventide Asset Management LLC boosted its stake in Blueprint Medicines by 50.5% in the third quarter. Eventide Asset Management LLC now owns 348,704 shares of the biotechnology company’s stock valued at $32,255,000 after acquiring an additional 117,019 shares during the last quarter.

Blueprint Medicines Stock Down 1.3 %

Blueprint Medicines stock opened at $93.94 on Friday. The firm has a market capitalization of $5.97 billion, a PE ratio of -44.52 and a beta of 0.62. The company’s 50-day moving average is $99.61 and its 200-day moving average is $94.57. Blueprint Medicines Co. has a fifty-two week low of $77.57 and a fifty-two week high of $121.90. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. Sell-side analysts anticipate that Blueprint Medicines Co. will post -3.63 earnings per share for the current year.

Analyst Ratings Changes

BPMC has been the topic of a number of recent analyst reports. Wedbush reissued an “outperform” rating and set a $128.00 price target (up from $124.00) on shares of Blueprint Medicines in a research report on Thursday. UBS Group initiated coverage on shares of Blueprint Medicines in a research report on Thursday, October 24th. They set a “neutral” rating and a $88.00 price target on the stock. StockNews.com cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Friday. JMP Securities reissued a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a research report on Friday. Finally, Stephens reissued an “overweight” rating and set a $140.00 price target on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Blueprint Medicines has an average rating of “Moderate Buy” and an average price target of $123.83.

Insider Transactions at Blueprint Medicines

In related news, insider Ariel Hurley sold 1,819 shares of Blueprint Medicines stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $93.26, for a total transaction of $169,639.94. Following the completion of the sale, the insider now owns 14,967 shares of the company’s stock, valued at approximately $1,395,822.42. The trade was a 10.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Kate Haviland sold 1,446 shares of Blueprint Medicines stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the sale, the chief executive officer now directly owns 149,378 shares of the company’s stock, valued at $16,467,430.72. The trade was a 0.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 49,851 shares of company stock worth $4,984,696 in the last ninety days. Insiders own 4.21% of the company’s stock.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.